Biofrontera Inc (BFRI) Stock Price, Quote & News

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatmen...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 245 1325

Website: www.biofrontera-us.com

Address:

120 Presidential Way, Suite 330, Woburn, United States

james899 Nov. 14 at 7:06 PM

$BFRI ivo since you're bashing BFRI since years I would like to know why you still follow the company? I just cannot imagine your life and I wonder what's your purpose? I don't mean this in an attacking way, I just honestly don't understand your day? Are you waiting for something? Which companies do you invest in if not BFRI? Why do you still care about the development of BFRI?

0 · Reply

Elaine_Shrimp Nov. 14 at 4:48 PM

$BFRI only acquired 20k additional shares in this morning 🫩🫩🫩 Coward dont even have the gut to control the market

0 · Reply

ivo98 Nov. 14 at 10:07 AM

$BFRI They need Q4 revenues of $12,697,000 to achieve turnover to make FY 2025 equal to FY 2024. Won't work 🤣

0 · Reply

ivo98 Nov. 14 at 9:55 AM

$BFRI @Stereo August 25 is the day when more shares were diluted. + 1 mlj shares between 13 August and Q3 ER. Acne phase 2, it will take at least 2,5 years for phase 3 (if) approval and to bring it to market. BFRI has only 1 product, and even with Ameluz's annual 5% price increase, they fail to achieve high sales growth figures.

0 · Reply

Stereo Nov. 14 at 12:24 AM

On Friday August 22nd, 2025 $BFRI completed their Phase 2 Acne Vulgaris Study. On Monday August 25th, 2025 $BFRI experienced a 5.79 Million share spike in Buy Volume. Know what you own.

0 · Reply

Elaine_Shrimp Nov. 13 at 3:54 PM

$BFRI boring ... They apparently are hunting for stop loss shares 🥱🥱🥱 They do not have the gut to do anything lol dumbas

0 · Reply

SimSimBola Nov. 13 at 1:43 PM

$BFRI they keep sucking the money out. Herman like the EU are taking as much as they can from US. the company is always low on cash. fxckin crooks!

0 · Reply

ivo98 Nov. 13 at 1:40 PM

$BFRI bad numbers 👎

0 · Reply

Elaine_Shrimp Nov. 12 at 8:29 PM

$BFRI just MM bid/ask matrix to bring price down .. the ask fan orders will disappear when they done accum Still accum in stealth mode

0 · Reply

ivo98 Nov. 12 at 7:46 PM

$BFRI If the numbers are bad, I expect share back below $0.8 tomorrow. Cash could be better 🤔 Good luck tomorow. Waiting at the sideline 🤗

0 · Reply

Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 8:15 AM EST - 1 day ago

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Nov 7, 2025, 8:00 AM EST - 7 days ago

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Nov 6, 2025, 4:01 PM EST - 8 days ago

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

Oct 23, 2025, 8:45 AM EDT - 22 days ago

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Sep 26, 2025, 9:15 AM EDT - 7 weeks ago

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 23, 2025, 9:20 AM EDT - 7 weeks ago

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

Sep 16, 2025, 10:30 AM EDT - 2 months ago

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Aug 25, 2025, 8:25 AM EDT - 2 months ago

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Aug 14, 2025, 12:36 PM EDT - 3 months ago

Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript

Aug 13, 2025, 5:20 PM EDT - 3 months ago

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Aug 11, 2025, 4:25 PM EDT - 3 months ago

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Aug 4, 2025, 2:00 PM EDT - 3 months ago

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Jun 30, 2025, 8:00 AM EDT - 4 months ago

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment

Jun 11, 2025, 3:00 PM EDT - 5 months ago

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Jun 3, 2025, 2:30 PM EDT - 5 months ago

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

May 16, 2025, 3:36 PM EDT - 6 months ago

Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript

May 15, 2025, 5:09 PM EDT - 6 months ago

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

May 15, 2025, 12:17 PM EDT - 6 months ago

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

May 6, 2025, 12:45 PM EDT - 6 months ago

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

May 1, 2025, 2:38 PM EDT - 7 months ago

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Mar 21, 2025, 11:20 AM EDT - 8 months ago

Biofrontera Inc. (BFRI) Q4 2024 Earnings Call Transcript

Mar 21, 2025, 8:00 AM EDT - 8 months ago

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Mar 18, 2025, 9:30 AM EDT - 8 months ago

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Mar 11, 2025, 10:00 AM EDT - 8 months ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Jan 8, 2025, 9:50 AM EST - 11 months ago

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Dec 23, 2024, 9:30 AM EST - 11 months ago

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Dec 3, 2024, 11:00 AM EST - 1 year ago

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 22, 2024, 9:10 AM EST - 1 year ago

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Nov 14, 2024, 3:02 PM EST - 1 year ago

Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 5:15 PM EST - 1 year ago

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Nov 1, 2024, 11:55 AM EDT - 1 year ago

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024

Oct 31, 2024, 10:32 AM EDT - 1 year ago

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 14, 2024, 10:30 AM EDT - 1 year ago

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Oct 7, 2024, 8:45 AM EDT - 1 year ago

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Sep 25, 2024, 10:45 AM EDT - 1 year ago

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

Aug 15, 2024, 1:34 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 9, 2024, 10:00 AM EDT - 1 year ago

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

May 16, 2024, 2:44 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:45 PM EDT - 1 year ago

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

May 6, 2024, 10:30 AM EDT - 1 year ago

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

May 3, 2024, 8:50 AM EDT - 1 year ago

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Mar 26, 2024, 4:30 PM EDT - 1 year ago

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Mar 18, 2024, 12:13 PM EDT - 1 year ago

Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript

Mar 15, 2024, 8:25 PM EDT - 1 year ago

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 15, 2024, 6:10 PM EDT - 1 year ago

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Mar 8, 2024, 9:00 AM EST - 1 year ago

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Mar 5, 2024, 7:30 AM EST - 1 year ago

Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer

james899 Nov. 14 at 7:06 PM

0 · Reply

Elaine_Shrimp Nov. 14 at 4:48 PM

$BFRI only acquired 20k additional shares in this morning 🫩🫩🫩 Coward dont even have the gut to control the market

0 · Reply

ivo98 Nov. 14 at 10:07 AM

$BFRI They need Q4 revenues of $12,697,000 to achieve turnover to make FY 2025 equal to FY 2024. Won't work 🤣

0 · Reply

ivo98 Nov. 14 at 9:55 AM

0 · Reply

Stereo Nov. 14 at 12:24 AM

On Friday August 22nd, 2025 $BFRI completed their Phase 2 Acne Vulgaris Study. On Monday August 25th, 2025 $BFRI experienced a 5.79 Million share spike in Buy Volume. Know what you own.

0 · Reply

Elaine_Shrimp Nov. 13 at 3:54 PM

$BFRI boring ... They apparently are hunting for stop loss shares 🥱🥱🥱 They do not have the gut to do anything lol dumbas

0 · Reply

SimSimBola Nov. 13 at 1:43 PM

$BFRI they keep sucking the money out. Herman like the EU are taking as much as they can from US. the company is always low on cash. fxckin crooks!

0 · Reply

ivo98 Nov. 13 at 1:40 PM

$BFRI bad numbers 👎

0 · Reply

Elaine_Shrimp Nov. 12 at 8:29 PM

$BFRI just MM bid/ask matrix to bring price down .. the ask fan orders will disappear when they done accum Still accum in stealth mode

0 · Reply

ivo98 Nov. 12 at 7:46 PM

$BFRI If the numbers are bad, I expect share back below $0.8 tomorrow. Cash could be better 🤔 Good luck tomorow. Waiting at the sideline 🤗

0 · Reply

StockHolms Nov. 12 at 5:31 PM

$PHGE Holding two stocks with earnings this week - $PHGE AND $BFRI. Not a fan 😬 of earnings for these micros but it is what it is. Holding the line between respecting my risk and being patient with conviction. I think both names have potential to produce sweet gains. Typically, big moves don’t come from earnings on these biotechs because they are all cash strapped. Keeping size in check lessens the emotional attachment. Staying patient can be difficult. SEND IT!!

0 · Reply

StockHolms Nov. 11 at 8:40 PM

$BFRI Send it!

0 · Reply

Revo31 Nov. 11 at 7:33 PM

$BFRI

1 · Reply

MrTicker Nov. 11 at 7:09 PM

$BFRI could see a bump during power hour or after hours in anticipation of ER.. keep an eye on this

0 · Reply

ivo98 Nov. 11 at 9:02 AM

@james899 nope. Max. $BFRI outstanding in Q3 ER +/- 12 to 15 mlj. Diluted shares for calculation Q3 will be +/- 9 to 10 mlj. Prospects (future) are still not bright 🤔🥺 Selling some % of my holding today. I prefer ER before market, not after. Good luck

0 · Reply

ChiArt Nov. 10 at 5:07 PM

$BFRI anybody else get a random text for this a week or so ago? They want exit liquidity?

3 · Reply

Revo31 Nov. 10 at 1:03 PM

$BFRI Low floater let’s move the needle . Earnings this week!

0 · Reply

ivo98 Nov. 7 at 3:01 PM

@james899 one quarter of profit on an annual basis does not make $BFRI a profitable company. Hopefully they don't come with bad news next week with Q3 ER. They have requested an extension of 4 and 7 days to file complaint after date November 17, 2025. 🤔🤫

1 · Reply

Bcscoatings Nov. 7 at 1:11 PM

$BFRI news and it’s dropping 😑

0 · Reply

makedatbread88 Nov. 7 at 1:02 PM

$BFRI low floater with great news!

0 · Reply

Stock_Catcher Nov. 7 at 1:00 PM

$BFRI low float Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

0 · Reply

MrTicker Nov. 7 at 12:56 PM

$BFRI EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch BENZINGA 6:52 AM ET 11/7/2025

0 · Reply

Market Cap	10.37M
Revenue (ttm)	37.32M
Net Income (ttm)	-17.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-47.59%
Debt to Equity Ratio	-0.93

Volume	262,800
Avg Vol	141,406
Day's Range	N/A - N/A
Shares Out	11.65M
Stochastic %K	5%
Beta	0.55
Analysts	Strong Sell
Price Target	$6.00